Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression (Q34381557)

1 August 2017

title

Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression (English)

1 reference

1 August 2017

0 references

Michael Paulzen

0 references

Tanja Veselinović

1 reference

1 August 2017

Gerhard Gründer

series ordinal

1 reference

1 August 2017

publication date

1 November 2013

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

1 August 2017

published in

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

1141-1159

1 reference

The global prevalence of schizophrenia

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

The primacy of cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Possible interrelationship between release of brain norepinephrine and serotonin by reserpine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

A history of antipsychotic drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Functional Selectivity and Classical Concepts of Quantitative Pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

The 'atypicality' of antipsychotics: a concept re-examined and re-defined

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Molecular targets for treating cognitive dysfunction in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Dopamine D3 receptor antagonists as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Definitions of response and remission in schizophrenia: recommendations for their use and their presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Selective dopamine D3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2013.853448

10.1586/14737175.2013.853448

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference